Table 2. Characteristics of 4 patients infected with oseltamivir-resistant pandemic influenza A (H1N1) virus isolates, Australia*†.
| Characteristic | Patient no. |
|||
|---|---|---|---|---|
| 1 | 5 | 12 | 20 | |
| Within 100 days of HSCT‡ | No | Yes | No | – |
| Time to development of resistance, d | 22 | 11§ | 8 | 4 |
| Time of last positive NAT result, d | 28 | 16 | 8 | 4 |
| Change to zanamivir | Yes | No | No | No |
| Time to zanamivir, d | 36 | – | – | – |
| Died | Yes | Yes | No | No |
| LOS, d | 39 | 66 | 21 | 9 |
*HSCT, hematopoietic stem cell transplant; NAT, nucleic acid test; LOS, length of stay. †Oseltamivir resistance was influenza virus with H275Y mutation. ‡Time from commencement of oseltamivir. §Detected in bronchoalveolar lavage specimen with negative NAT on nasopharyngeal swab 3 d before first and 10 d after last bronchoscopy. This patient received oseltamivir for 5 d.